Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
TG Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07503873CT.gov A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | — | Not Yet Recruiting | — | — | — |
NCT07389590CT.gov Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | — | Recruiting | — | — | — |
NCT07225361CT.gov Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis | — | Recruiting | — | — | — |
NCT06681623CT.gov A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS) | — | Recruiting | — | — | — |
NCT02738775CT.gov Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ublituximab (this asset) | TG Therapeutics, Inc. | Approved | CCC · 52 |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Ublituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BB · 66 |
| Marginal Zone Lymphoma | — | P2/3 | B · 57 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ublituximab in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ublituximab-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →